Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt

• Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616…

Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Pancreas (43.0%), biliary tract (30.6%), salivary glands (11.7%), retroperitoneum (5.0%). HR 2.51 for mortality in IgG4-RD. @RheumNow #ACR22 Abstr#0713 https://t.co/IpjSKxmHQN

• The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG…

Opioid use in adults with PsA and AS Abstract #0402 @RheumNow #ACR22 ✋828 PsA patients ➡️ 21% used opioids 🦴 334 AS patients ➡️ 27% used opioids 💊Opioid users had more comorbidities, more medical visits, worse disease activity, and higher prevalence of 🚬

Manansala et al. Baseline lymphopenia negatively predicts disease severity in sarcoid. It is protective for decline in FBC. @RheumNow #ACR22 Abstr#0830 https://t.co/Q4fE9LoG9L https://t.co/Tt1PyYLfWu

• Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis - ACR M…

Ross et al. Comorbid liver disease significantly attenuates CRP rise with disease flare. Increased BMI increases CRP rise. @RheumNow #ACR22 Abstr#0811 https://t.co/O3PsDfbCMV https://t.co/9xAqWTJqkf

• Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated I…

Fat and bone health are related via adipokines (fat hormones). Data from VA registry of RA pts: clear relationship between elevated adipokines & osteoporotic fracture risk. This is why body fat should be a target for osteoporosis management ABST0889 @PennRheum #ACR22 @RheumNow https://t.co/BoP8d4sooZ

Vural et al Rituximab biosimilar switch in GPA. Essentially it is the same. @RheumNow #ACR22 Abstr#1072 https://t.co/OBOMz35soX https://t.co/dPdcWQmBzd

• Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granu…

Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish study. But to greater extent in RA, narrowing mortality gap. @RheumNow #ACR22 Abstr#0711 https://t.co/JRh37u3uGm https://t.co/bA3Y5FLcRZ

• Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the …

Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular characterization of individual SLE pts and it's extraction of key molecular information to support more precise therapeutic decisions. #ACR22 @RheumNow https://t.co/FslQCVvptw https://t.co/NNlgZvllPC

• http://ow.ly/GEcK50Lvyp2
• Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus …

🔥ignite session🔥 ❓Vessel wall MRI superior to TA-US in c-GCA❓ 🔥In c-GCA vessel wall MRI examines beyond the temporal arteries - ✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures Abst#0473 #ACR22 @RheumNow https://t.co/z8hYmqc95I

Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/Od1PXzJKQh https://t.co/Hk8mrblGMX

• Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneou…

Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis KEEPsAKE 1&2 - RZB v PBO 1407 pts -baseline 63% enth, 28% dact, 20% both Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both Mean time to resolution decreased Results maintained through wk 52 @RheumNow https://t.co/RBubeuJoh8

Frey @CaoilfhionnMD @JuliePaikMD et al. Increasing duration of hold of MMF (esp >=10 days) increased response to SARS-CoV-2 vaccine. No difference in disease flare rates. @RheumNow #ACR22 Abstr#0797 https://t.co/5nxo2nLg80 https://t.co/sx1Roxngx9

• Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV…

In this prospective cohort study by Dr Jacquez, there was a statistically significant inverse assoc bet. average yearly HCQ dose and overall damage accrual 👇 Reassuring data. ☝️HCQ consistently proves to be a beneficial drug for #lupus #ACR22 @Rheumnow ABST#0982 @rheumarhyme https://t.co/nWHS9JtEsH

Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after completion. Cited reasons: ongoing preparation/review of paper (50%), sponsor/funder problems (40%), unimportant/negative result (20%).@RheumNow #ACR22 Abstr#0827 https://t.co/V2a48iiAcn https://t.co/FLqQhjvlOx

• Unpublished Clinical Trials of Major Rheumatic Diseases - ACR Meeting Abstracts